Eczema (atopic dermatitis) clinical trials, in English

This is a tissue, urine, and blood banking protocol for cutaneous t-cell lymphoma (CTCL), eczema, and atopic dermatitis patients for current and future research.

NCT00177268 · Official ClinicalTrials.gov record · University of Pittsburgh

This study will examine microbes (e.g., bacteria, fungi, viruses) that live on human skin and how microbes contribute to health and disease. It will analyze healthy human skin and how the these microorganisms might change in patients with atopic dermatitis (AD), a skin condition also known as eczema.

NCT00605878 · Official ClinicalTrials.gov record · National Human Genome Research Institute (NHGRI)

Background: \- Atopic dermatitis, or eczema, is a chronic skin disorder. Patients sometimes have infections with S.

NCT01631617 · Official ClinicalTrials.gov record · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Background: \- About 15 million Americans have a food allergy. Because there are no cures or effective prevention or treatment for food allergies, researchers want to learn more about them.

NCT02504853 · Official ClinicalTrials.gov record · National Institute of Allergy and Infectious Diseases (NIAID)

Background: The immune system is the part of the body that fights infection. Some people have immune deficiencies that cause skin rashes, make them get sick often with infections, or make it difficult for their skin to heal.

NCT04864886 · Official ClinicalTrials.gov record · National Institute of Allergy and Infectious Diseases (NIAID)

The skin microbiome plays a role in the pathogenesis of atopic dermatitis. However, it is unclear whether the range of microbiota on the skin is the cause or consequence of atopic skin inflammation.

NCT05099315 · Official ClinicalTrials.gov record · Charite University, Berlin, Germany

This study examines the effect of IL4RA blockade with dupilumab on the immune cells of atopic dermatitis skin lesions.

NCT05858619 · Official ClinicalTrials.gov record · University of California, San Francisco

The purpose of the study is to collect different samples for molecular characterization of inflammatory skin diseases.

NCT05994976 · Official ClinicalTrials.gov record · Innovaderm Research Inc.

Background: Atopic dermatitis (AD), also called eczema, is a chronic skin condition. AD can make skin dry and itchy, and sometimes it can lead to serious health problems, such as asthma, food allergies, eye infections, and sleep problems.

NCT06096857 · Official ClinicalTrials.gov record · National Institute of Allergy and Infectious Diseases (NIAID)

In adolescents treated with dupilumab, clinical trials showed significant improvement of atopic dermatitis (AD) signs and symptoms, with a good safety profile. In these clinical trials, only patients with Eczema Area and Severity Index (EASI) score greater than or equal to (≥) 16 were enrolled, and effectiveness on sensitive/visible areas was not specifically evaluated.

NCT06192563 · Official ClinicalTrials.gov record · Sanofi

This study will explore potential links between atopic dermatitis and food allergy. This information will be useful to determine atopic dermatitis and food allergy share unique biochemical or genetic identifiers useful for diagnosing and treatments in the future.

NCT06300697 · Official ClinicalTrials.gov record · University of Michigan

The purpose of this trial is to test whether treatment with tralokinumab (administered subcutaneous injections \[SC\]) in combination with topical corticosteroids (TCS) is safe and effective to treat moderate-to-severe atopic dermatitis (AD) in children and infants. This will be judged by a range of assessments that rate the severity and extent of atopic dermatitis and its symptoms, as well as general health status and quality of life.

NCT06311682 · Official ClinicalTrials.gov record · LEO Pharma

Atopic dermatitis (AD) is as chronic, inflammatory skin disorder affecting 20% of the world's population. Intense itch and skin pain are the main symptoms.

NCT06503510 · Official ClinicalTrials.gov record · Aalborg University

The purpose of the study is to measure the safety, tolerability, and pharmacokinetics of escalating single and repeat doses of PF-07832837 in healthy participants and in participants with moderate to severe atopic dermatitis. An additional goal is to assess the pharmacodynamics of PF-07832837 in participants with moderate to severe AD, including potential effects on clinical signs and symptoms

NCT06564389 · Official ClinicalTrials.gov record · Pfizer

This 24-month study will assess the long-term safety and how well it works of liquid abrocitinib oral suspension with or without topical medications in children 2 years of age or older with moderate-to-severe atopic dermatitis. The study will enroll two groups: participants who have completed other abrocitinib studies and participants who have never participated in abrocitinib studies.

NCT06807281 · Official ClinicalTrials.gov record · Pfizer

This Phase 1a/1b randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment study evaluates the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of subcutaneously (SC) administered TRB-061 in healthy adults and patients with moderate-to-severe atopic dermatitis (AD). The number of dosing cohorts may be increased or decreased in Part 1 (SAD) or Part 2 (MAD).

NCT06934252 · Official ClinicalTrials.gov record · TRex Bio, Inc.

This is a multicenter, neither you nor the study doctors know who gets the real treatment, Long-Term Extension (LTE) study to measure the long-term safety and how well it works of APG777 in patients with moderate-to-severe AD who have completed treatment in an APG777 Parent Study (NCT06395948). The LTE study will consist of 3 periods: 1) Screening Visit will coincide with the last visit of the Maintenance Period in the Parent Study 2) Extended Treatment Period 3) Post-treatment Follow-up Period.

NCT07003425 · Official ClinicalTrials.gov record · Apogee Therapeutics, Inc.

The goal of this watch-and-measure (no experimental treatment required) study is to comprehensively profile six immune-mediated inflammatory diseases, including atopic dermatitis (AD), plaque psoriasis (PSO), hidradenitis suppurativa (HS), cutaneous T-cell lymphoma subtype mycosis fungoides (MF), chronic spontaneous urticaria (CSU), and cutaneous lupus erythematosus (CLE) in daily practice. Data will be compared with data from healthy volunteers.

NCT07021495 · Official ClinicalTrials.gov record · Leiden University Medical Center

This study wants to learn if the study medicine (PF-08049820) is safe and effective for the treatment of atopic dermatitis (AD), also known as eczema, or atopic eczema. People with this condition may have severe itching and rashes on the skin.

NCT07216027 · Official ClinicalTrials.gov record · Pfizer

This is a phase 1/1b randomly assigned, double blind, compared with a dummy treatment, single dose escalation (SAD) and multiple dose escalation (MAD) study to measure the safety, tolerability, and pharmacokinetics (PK) of ZL-1503 in healthy volunteers and participants with moderate to severe atopic dermatitis (AD)

NCT07235384 · Official ClinicalTrials.gov record · Zai Lab (Shanghai) Co., Ltd.

Background: Autosomal dominant hyper-IgE syndrome (HIES), also called Job syndrome, is a genetic disorder that affects the immune system. It can cause skin and lung infections and problems with blood vessels, connective tissues, and bones.

NCT07262983 · Official ClinicalTrials.gov record · National Institute of Allergy and Infectious Diseases (NIAID)

The objectives of this prospective non-treatment study are to characterize the existing unmet needs across the spectrum of atopic dermatitis (AD), enhance the understanding of the patient journey, and measure the safety and clinical outcomes of systemic AD treatments in a real-world setting. Additionally, patient-specific factors (such as age, skin color, AD flare triggers, previous treatment responses, comorbid conditions, and the extent and site of lesions) will be assessed to better characterize the impact on the treatment journey across a broad age range and diverse geographic regions.

NCT07290803 · Official ClinicalTrials.gov record · Sanofi

This is a a multicenter, randomly assigned, double-blinded, parallel, positive-controlled, Phase III comparative study to evaluate GS101 Injection versus Dupixent® in participants with moderate-to-severe atopic dermatitis. A total of 572 subjects are planned to be included and randomly assigned at a ratio of 1:1 to receive GS101 injection or Dupixent®

NCT07386743 · Official ClinicalTrials.gov record · Jiangsu Genscend Biopharmaceutical Co., Ltd

This is a first-in-human, Phase 1, neither you nor the study doctors know who gets the real treatment, randomly assigned, compared with a dummy treatment, dose-escalation study evaluating ARQ-234. The study is designed to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ARQ-234 in two populations: healthy volunteers and participants with moderate to severe atopic dermatitis (AD).

NCT07453602 · Official ClinicalTrials.gov record · Arcutis Biotherapeutics, Inc.

This study aims to assess the impact of dupilumab on the mental health and quality of life of moderate-to-severe Atopic Dermatitis (AD) patients. The study will recruit participants from AD patients who are already receiving dupilumab treatment.

NCT07467564 · Official ClinicalTrials.gov record · Sanofi

This study will test an experimental study medicine called REGN20423 to see how effective it is in healthy participants (in Part A) and participants with atopic dermatitis (eczema) (in Part B). REGN20423 is a study medicine that is only used in clinical studies.

NCT07527923 · Official ClinicalTrials.gov record · Regeneron Pharmaceuticals

The purpose of this first-in-human (FIH) study is to assess the whether it is safe and how hard side effects are to live with, pharmacokinetics (PK), immunogenicity (IG) and pharmacodynamics (PD) of DCY636. The results are intended to support the further clinical development of DCY636 in future studies.

NCT07604324 · Official ClinicalTrials.gov record · Novartis Pharmaceuticals

This study will collect skin measurements from people with atopic dermatitis (AD) using the investigational Nevisense Go device. Participants aged 12 to 89 years with a history of AD flares will use the device at home for about 90 days.

NCT07645820 · Official ClinicalTrials.gov record · Castle Biosciences Incorporated

Atopic dermatitis is well reported to have a significant impact on well-being in adolescents with atopic dermatitis, without clear recommendations for intervention. The investigators aim to identify an accessible, effective digital health intervention for these patients.

NCT07746427 · Official ClinicalTrials.gov record · Weill Medical College of Cornell University

This study is expected to include approximately 520 patients with moderate to severe AD, and they will be randomly assigned to the treatment group (IBI3027) and the control group (Dupilumab Injection ) in a 1:1 ratio. Study period: It includes a screening period (4 weeks), a treatment period (44 weeks), and a follow-up period (8 weeks).

NCT07754786 · Official ClinicalTrials.gov record · Innovent Biologics (Suzhou) Co. Ltd.

The goal of this treatment study is to learn if TRIV-573 works to treat moderate to severe atopic dermatitis in adults. It will also measure the safety of TRIV-573.

NCT07782333 · Official ClinicalTrials.gov record · Triveni Bio

This study wants to find out how well tilrekimig works, how safe it is, and how it affects the body in adults and adolescents with moderate to severe atopic dermatitis (eczema). Eczema is a condition which can cause dryness, itching, and redness of your skin.

NCT07783425 · Official ClinicalTrials.gov record · Pfizer

This study will measure the safety, tolerability, pharmacokinetics and immunogenicity of PRA-216 compared to dummy treatment (placebo) in patients with moderate to severe Atopic Dermatitis (AD)

NCT07810777 · Official ClinicalTrials.gov record · Prana Therapies Inc

The goal of this clinical trial is to learn if drug LT-002-158 works to treat moderate-to-severe atopic dermatitis in adults. It will also learn about the safety of drug LT-002-158.

NCT07895615 · Official ClinicalTrials.gov record · Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.

Atopic dermatitis is a chronic inflammatory skin disease associated with intense pruritus, recurrent eczematous lesions, sleep disturbance, and reduced quality of life. The disease may be influenced by genetic factors, environmental triggers, epidermal barrier dysfunction, and immune dysregulation.

NCT07904546 · Official ClinicalTrials.gov record · Universitätsklinikum Hamburg-Eppendorf

Nocturnal scratching is a frequent and meaningful symptom in dermatological conditions such as atopic dermatitis. It may reflect underlying disease activity and can substantially disrupt overall sleep and quality of life.

NCT07909967 · Official ClinicalTrials.gov record · Replior AB

This study is composed of a two-arm, neither you nor the study doctors know who gets the real treatment, randomly assigned, compared with a dummy treatment, Phase II study to measure the how well it works of AR100DP1 compared to dummy treatment (placebo) on AD lesion area(s) in subjects with mild to moderate AD.

NCT07914088 · Official ClinicalTrials.gov record · Arjil Pharmaceuticals LLC

This Phase 3 study is designed to measure the how well it works and safety of once-daily roflumilast cream 0.3% in children, adolescents, and adults with moderate to severe atopic dermatitis. Approximately 415 you would be randomly assigned in a 2:1 ratio to receive roflumilast cream 0.3% or matching vehicle cream during a 4-week neither you nor the study doctors know who gets the real treatment, vehicle-controlled treatment period.

NCT07916480 · Official ClinicalTrials.gov record · Arcutis Biotherapeutics, Inc.